{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:52:57Z","timestamp":1790837577883,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007791.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000}}],"reference-count":57,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007791.pub4","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T10:46:14Z","timestamp":1472553974000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pharmacological treatments for Friedreich ataxia"],"prefix":"10.1002","volume":"2016","author":[{"given":"Mary","family":"Kearney","sequence":"first","affiliation":[{"name":"Irish College of General Practitioners; General Practice; Dunlavin County Wicklow Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W","family":"Orrell","sequence":"additional","affiliation":[{"name":"University College London Institute of Neurology; Department of Clinical Neurosciences; Royal Free Campus Rowland Hill Street London UK NW2 3PF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fahey","sequence":"additional","affiliation":[{"name":"Monash University; Department of Paediatrics; Clayton Victoria Australia 3168"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Brassington","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; MRC Centre for Neuromuscular Diseases; PO Box 114 London UK WC1N 3BG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pandolfo","sequence":"additional","affiliation":[{"name":"Hopital Erasme, Universit\u00e9 Libre de Bruxelles; Neurology Department; Route de Lennik 808 Brussels Belgium 1070"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,30]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD007791.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1468-1331.2008.02318.x","article-title":"Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy","volume":"15","author":"Cooper","year":"2008","journal-title":"European Journal of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1212\/01.WNL.0000055872.50364.FC","article-title":"Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial","volume":"60","author":"Mariotti","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0003|cit3","unstructured":"NCT00811681 Effect of pioglitazone administered to patients with Friedreich's ataxia: proof of concept (ACTFRIE) clinicaltrials.gov\/ct2\/show\/NCT00811681"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0004|cit4","unstructured":"NCT00905268 A study of efficacy, safety and tolerability of idebenone in the treatment of Friedreich's ataxia (FRDA) patients (MICONOS) clinicaltrials.gov\/ct2\/show\/NCT00905268"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0005|cit5","unstructured":"Santhera Pharmaceuticals Santhera's MICONOS Trial with Catena\/Sovrima in Friedreich's Ataxia misses Primary Endpoint http:\/\/www.santhera.com\/index.php?docid=212&vid=&lang=&newsdate=201005&newsid=1417424&newslang=en"},{"issue":"13","key":"10.1002\/14651858.CD007791.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.111.059477","article-title":"The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms","volume":"125","author":"Weidemann","year":"2012","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","article-title":"Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial","volume":"6","author":"Prospero","year":"2007","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007791.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ahj.2010.10.038","article-title":"Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)","volume":"161","author":"Lagedrost","year":"2011","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD007791.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia","volume":"67","author":"Lynch","year":"2010","journal-title":"Archives of Neurology"},{"issue":"s3","key":"10.1002\/14651858.CD007791.pub4-BIB0010|cit10","first-page":"598","article-title":"Erythropoietin in patients with Friedreich's ataxia: results of a randomized, double-blind, placebo controlled, dose-finding clinical trial","volume":"17","author":"Mariotti","year":"2010","journal-title":"European Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial","volume":"76","author":"Pandolfo","year":"2014","journal-title":"Annuals of Neurology"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00702-004-0216-x","article-title":"L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial","volume":"112(6)","author":"Sch\u00f6ls","year":"2005","journal-title":"Journal of Neural Transmission"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ane.12141","article-title":"Triple therapy with deferiprone, idebenone and riboflavin in Friedriech's ataxia - open-label trial","volume":"129","author":"Arpa","year":"2014","journal-title":"Acta Neurologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1055\/s-2002-34494","article-title":"Friedreich's ataxia: idebenone treatment in early stage patients","volume":"33","author":"Artuch","year":"2002","journal-title":"Neuropediatrics"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0015|cit15","unstructured":"Joint Formulary Committee British National Formulary British National Formulary (online). London: BMJ Group and Pharmaceutical Press www.evidence.nhs.uk\/formulary\/bnf\/current\/8-malignant-disease-and-immunosuppression\/82-drugs-affecting-the-immune-response\/824-other-immunomodulating-drugs\/interferon-gamma"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: biological and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD007791.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21177","article-title":"Friedreich's ataxia; clinical pilot trial with recombinant human erythropoietin","volume":"62","author":"Boesch","year":"2007","journal-title":"Annuals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD007791.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25836","article-title":"Safety and tolerability of carbamylated erythropoetin in patients with Friedreich's ataxia","volume":"29","author":"Boesch","year":"2014","journal-title":"Movement Disorders"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub4-BIB0019|cit19","first-page":"1569","article-title":"Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring","volume":"60","author":"Buyse","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD007791.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/mds.22660","article-title":"Comparison of three clinical rating scales in Friedreich Ataxia (FRDA)","volume":"24","author":"B\u00fcrk","year":"2009","journal-title":"Movement Disorders"},{"issue":"5254","key":"10.1002\/14651858.CD007791.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's Ataxia: Autosomal Recessive Disease caused by an Intronic GAA Triplet Repeat Expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes","volume":"6","author":"Campuzano","year":"1997","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0023|cit23","unstructured":"Clinical Trials.gov Friedreich ataxia clinicaltrials.gov\/ct2\/results?term=friedreich+ataxia&pg=1 May 2015"},{"issue":"6","key":"10.1002\/14651858.CD007791.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ana.23698","article-title":"Central role and mechanism of \u00df-cell dysfunction and death in Freidreich ataxia-associated diabetes","volume":"72","author":"Cnop","year":"2012","journal-title":"Annals of Neurology"},{"issue":"16","key":"10.1002\/14651858.CD007791.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","article-title":"Clinical and Genetic Abnormalities in Patients with Friedreich's Ataxia","volume":"335","author":"D\u00fcrr","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0026|cit26","unstructured":"European Medicines Agency Sovrima: EPAR - Public assessment report. EMEA\/387246\/2009 ema.europa.eu"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.55.11.1752","article-title":"Increased levels of plasma malondialdehyde in Friedreich ataxia","volume":"55","author":"Emond","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0028|cit28","first-page":"205","article-title":"How is disease progress in Friedreich's ataxia best measured? A study of four rating scales","volume":"78","author":"Fahey","year":"2006","journal-title":"Jounrnal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00280-013-2084-2","article-title":"The PPARy agonist pioglitazone crossed the blood brain barrier and reduces tumor growth in a human xenograft model","volume":"4","author":"Grommes","year":"2013","journal-title":"Cancer Chemotherapy Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"American Journal Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/heart.87.4.346","article-title":"Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia","volume":"87","author":"Hausse","year":"2002","journal-title":"Heart"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0032|cit32","unstructured":"Summary Basis of Decision (SBD) for Pr CATENA hc-sc.gc.ca\/dhp-mps\/prodpharma\/sbd-smd\/drug-med\/sbd_smd_2009_catena_117672-eng.php"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nchembio815","article-title":"Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia","volume":"2","author":"Herman","year":"2006","journal-title":"Nature Chemical Biology"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0034|cit34","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"13","key":"10.1002\/14651858.CD007791.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1182\/blood-2008-06-161919","article-title":"Cell function impaired by frataxin deficiency are restored by drug-mediated iron chelation","volume":"112","author":"Kakhlon","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Kemp K Mallam E Hares K Witherick J Scolding N Wilkins A Mesenchymal Stem Cells Restore Frataxin Expression and Increase Hydrogen Peroxide Scavenging Enzymes in Friedreich Ataxia Fibroblasts PLoS ONE (plosone.org) 2011 e26098 10.1371\/journal.pone.0026098","DOI":"10.1371\/journal.pone.0026098"},{"issue":"9942","key":"10.1002\/14651858.CD007791.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","article-title":"Epigentic and neurological effects and safety of high-doe nicotinamide in patients with Friedreich's ataxia: an exploratory, open label, dose-escalation study","volume":"384","author":"Libri","year":"2014","journal-title":"The Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0008-6363(01)00357-1","article-title":"Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study","volume":"52","author":"Lodi","year":"2001","journal-title":"Cardiovascular Research"},{"issue":"25","key":"10.1002\/14651858.CD007791.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1093\/hmg\/ddt370","article-title":"A GAA repeat expansion reporter model of Friedreich's ataxia recapitulates the genomic context and allows rapid screening of therapeutic compounds","volume":"22","author":"Lufino","year":"2013","journal-title":"Human Molecular Genetics"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0040|cit40","unstructured":"Grogan M Efection Fraction:What does it measure? mayoclinic.org\/ejection-fraction\/expert-answers\/faq-20058286"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s12311-011-0287-9","article-title":"Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia--a-dose-response trial","volume":"10","author":"Nachbauer","year":"2011","journal-title":"Cerebellum"},{"issue":"2","key":"10.1002\/14651858.CD007791.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncpneuro0704","article-title":"Drug Insight: antioxidant therapy in inherited ataxias","volume":"4","author":"Pandolfo","year":"2008","journal-title":"Natural Clinical Practice Neurology"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Perdomini M Belbellaa B Monassier L Reutenauer L Messaddeq N Cartier N Prevention and reversal of severe mitochondrial cardiomyopathy be gene therapy in a mouse model of Friedreich's ataxia Nature Medicine 2014 542-7 10.1038\/nm.3510","DOI":"10.1038\/nm.3510"},{"issue":"6","key":"10.1002\/14651858.CD007791.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ejpn.2007.11.006","article-title":"Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up","volume":"12","author":"Pineda","year":"2008","journal-title":"European Journal of Paediatric Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/archneur.64.4.558","article-title":"Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up","volume":"64","author":"Ribai","year":"2007","journal-title":"Archives of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub4-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/01.NT.0000451003.10471.a7","article-title":"HDAC inhibition appears safe in early trial on Friedreich's ataxia","volume":"14","author":"Robinson","year":"2014","journal-title":"Neurology Today"},{"issue":"9177","key":"10.1002\/14651858.CD007791.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(99)01341-0","article-title":"Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study","volume":"354","author":"Rustin","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mds.23435","article-title":"Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit","volume":"26","author":"Sacc\u00e0","year":"2010","journal-title":"Movement Disorder Society"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0049|cit49","unstructured":"Santhera Pharmaceuticals Santhera's MICONOS Trial with Catena\u00ae\/Sovrima\u00ae in Friedreich's Ataxia Misses Primary Endpoint [press release] lacaf.org\/santhera-trial-with-catena-in-friedreich-ataxia-misses-primary-endpoint\/"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.55.11.1719","article-title":"Oxidative stress in patients with Friedreich ataxia","volume":"55","author":"Schulz","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.24260","article-title":"Epigenetic therapy in Friedreich ataxia","volume":"76","author":"Soragni E. Miao","year":"2014","journal-title":"Annuals of Neurology"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0052|cit52","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/hmg\/dds110","article-title":"Interferon gamma upregulates frataxin and corrects the function deficits in a Freidreich ataxia model","volume":"13","author":"Tomassini","year":"2012","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD007791.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-510X(96)00231-6","article-title":"International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome","volume":"145","author":"Trouillas","year":"1997","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD007791.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich Ataxia","volume":"307","author":"Tsou","year":"2011","journal-title":"Journal of the Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007791.pub2","article-title":"Antioxidants and other pharmacological treatments for Friedreich ataxia","author":"Kearney","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub4-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007791.pub3","article-title":"Antioxidants and other pharmacological treatments for Friedreich ataxia","author":"Kearney","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007791.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007791.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T20:41:22Z","timestamp":1636576882000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007791.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,30]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007791.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,30]]}}}